G47Δ virus enhances the ability to induce anti-tumor immunity is a virus for the treatment of genetically modified cancer. It is a modified Herpes simplex virus (HSV-1). A γ34.5 gene and the ICP6 gene necessary for viral DNA synthesis are deleted. The number of patients with malignant glioma in Japan is 3,500.
Daiichi Sankyo news release, July 11, 2017
Daiichi Sankyo’s virus G47Δ is registered as a product for regenerative medicine for malignant glioma